Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 7 7 2020
medline: 13 4 2022
entrez: 7 7 2020
Statut: ppublish

Résumé

Depression is a highly prevalent and heterogeneous disorder. This study aims to determine whether depression with atypical features shows different heritability and different degree of overlap with polygenic risk for psychiatric and immuno-metabolic traits than other depression subgroups. Data included 30 069 European ancestry individuals from the UK Biobank who met criteria for lifetime major depression. Participants reporting both weight gain and hypersomnia were classified as ↑WS depression (N = 1854) and the others as non-↑WS depression (N = 28 215). Cases with non-↑WS depression were further classified as ↓WS depression (i.e. weight loss and insomnia; N = 10 142). Polygenic risk scores (PRS) for 22 traits were generated using genome-wide summary statistics (Bonferroni corrected p = 2.1 × 10-4). Single-nucleotide polymorphism (SNP)-based heritability of depression subgroups was estimated. ↑WS depression had a higher polygenic risk for BMI [OR = 1.20 (1.15-1.26), p = 2.37 × 10-14] and C-reactive protein [OR = 1.11 (1.06-1.17), p = 8.86 × 10-06] v. non-↑WS depression and ↓WS depression. Leptin PRS was close to the significance threshold (p = 2.99 × 10-04), but the effect disappeared when considering GWAS summary statistics of leptin adjusted for BMI. PRS for daily alcohol use was inversely associated with ↑WS depression [OR = 0.88 (0.83-0.93), p = 1.04 × 10-05] v. non-↑WS depression. SNP-based heritability was not significantly different between ↑WS depression and ↓WS depression (14.3% and 12.2%, respectively). ↑WS depression shows evidence of distinct genetic predisposition to immune-metabolic traits and alcohol consumption. These genetic signals suggest that biological targets including immune-cardio-metabolic pathways may be relevant to therapies in individuals with ↑WS depression.

Sections du résumé

BACKGROUND
Depression is a highly prevalent and heterogeneous disorder. This study aims to determine whether depression with atypical features shows different heritability and different degree of overlap with polygenic risk for psychiatric and immuno-metabolic traits than other depression subgroups.
METHODS
Data included 30 069 European ancestry individuals from the UK Biobank who met criteria for lifetime major depression. Participants reporting both weight gain and hypersomnia were classified as ↑WS depression (N = 1854) and the others as non-↑WS depression (N = 28 215). Cases with non-↑WS depression were further classified as ↓WS depression (i.e. weight loss and insomnia; N = 10 142). Polygenic risk scores (PRS) for 22 traits were generated using genome-wide summary statistics (Bonferroni corrected p = 2.1 × 10-4). Single-nucleotide polymorphism (SNP)-based heritability of depression subgroups was estimated.
RESULTS
↑WS depression had a higher polygenic risk for BMI [OR = 1.20 (1.15-1.26), p = 2.37 × 10-14] and C-reactive protein [OR = 1.11 (1.06-1.17), p = 8.86 × 10-06] v. non-↑WS depression and ↓WS depression. Leptin PRS was close to the significance threshold (p = 2.99 × 10-04), but the effect disappeared when considering GWAS summary statistics of leptin adjusted for BMI. PRS for daily alcohol use was inversely associated with ↑WS depression [OR = 0.88 (0.83-0.93), p = 1.04 × 10-05] v. non-↑WS depression. SNP-based heritability was not significantly different between ↑WS depression and ↓WS depression (14.3% and 12.2%, respectively).
CONCLUSIONS
↑WS depression shows evidence of distinct genetic predisposition to immune-metabolic traits and alcohol consumption. These genetic signals suggest that biological targets including immune-cardio-metabolic pathways may be relevant to therapies in individuals with ↑WS depression.

Identifiants

pubmed: 32624019
doi: 10.1017/S0033291720002342
pii: S0033291720002342
pmc: PMC8961332
doi:

Substances chimiques

Leptin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-736

Subventions

Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S0151132
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N015746/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S015132/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom

Références

Mol Psychiatry. 2016 Apr;21(4):516-22
pubmed: 26122587
Int J Methods Psychiatr Res. 2006;15(4):167-80
pubmed: 17266013
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Trends Endocrinol Metab. 2010 Nov;21(11):643-51
pubmed: 20846876
Nat Genet. 2017 Mar;49(3):403-415
pubmed: 28135244
Nat Genet. 2018 May;50(5):668-681
pubmed: 29700475
Eur Arch Psychiatry Clin Neurosci. 2002 Dec;252(6):288-93
pubmed: 12563537
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14372-14377
pubmed: 27911795
BJPsych Open. 2020 Feb 06;6(2):e18
pubmed: 32026800
Nat Genet. 2019 Aug;51(8):1207-1214
pubmed: 31308545
CNS Drugs. 2014 Jun;28(6):571-81
pubmed: 24715548
Genet Epidemiol. 2012 Apr;36(3):214-24
pubmed: 22714935
Nat Commun. 2019 Apr 2;10(1):1499
pubmed: 30940813
Am J Hum Genet. 2011 Mar 11;88(3):294-305
pubmed: 21376301
J Affect Disord. 2001 Jun;65(1):75-9
pubmed: 11426513
Nat Commun. 2016 Feb 01;7:10494
pubmed: 26833098
Gigascience. 2019 Jul 1;8(7):
pubmed: 31307061
Sci Rep. 2018 Feb 12;8(1):2861
pubmed: 29434331
Am J Psychiatry. 2000 Oct;157(10):1552-62
pubmed: 11007705
JAMA Psychiatry. 2017 Nov 1;74(11):1153-1160
pubmed: 28813562
Transl Psychiatry. 2014 Dec 02;4:e486
pubmed: 25463972
Arch Gen Psychiatry. 2003 Aug;60(8):817-26
pubmed: 12912765
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Am J Hum Genet. 2018 Nov 1;103(5):691-706
pubmed: 30388399
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
Am J Med Genet B Neuropsychiatr Genet. 2020 Sep;183(6):309-330
pubmed: 32681593
Psychol Med. 2020 Oct;50(14):2385-2396
pubmed: 31530331
Aust N Z J Psychiatry. 2009 Dec;43(12):1147-54
pubmed: 20001414
Mol Psychiatry. 2019 Jun;24(6):888-900
pubmed: 30824865
Front Neurosci. 2018 May 11;12:303
pubmed: 29867316
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Nat Neurosci. 2019 Mar;22(3):343-352
pubmed: 30718901
J Affect Disord. 2015 Feb 1;172:96-102
pubmed: 25451401
J Affect Disord. 2015 Oct 1;185:76-80
pubmed: 26148463
Am J Psychiatry. 1997 Jul;154(7):934-40
pubmed: 9210743
PLoS Genet. 2014 Apr 10;10(4):e1004269
pubmed: 24721987
J Clin Psychiatry. 2012 Feb;73(2):224-32
pubmed: 21939615
JAMA Psychiatry. 2014 Aug;71(8):880-8
pubmed: 24898270
JAMA Psychiatry. 2017 Dec 1;74(12):1214-1225
pubmed: 29049554
Bioinformatics. 2010 Nov 15;26(22):2867-73
pubmed: 20926424
Nat Genet. 2018 May;50(5):746-753
pubmed: 29662166
J Clin Invest. 2010 Aug;120(8):2931-41
pubmed: 20592471
Psychol Med. 2020 May;50(7):1129-1138
pubmed: 31044683
Nature. 2015 Feb 12;518(7538):197-206
pubmed: 25673413
Neuropsychiatr Dis Treat. 2017 Sep 20;13:2447-2456
pubmed: 29033570

Auteurs

Isabella Badini (I)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Jonathan R I Coleman (JRI)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

Saskia P Hagenaars (SP)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Matthew Hotopf (M)

National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

Gerome Breen (G)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

Cathryn M Lewis (CM)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Department of Medical and Molecular Genetics, King's College London, London, UK.

Chiara Fabbri (C)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH